Risk factors

68 risks, 22 new, 12 dropped, 8 reworded since the prior year. Bitcoin treasury risks now dominate, including pledged collateral, volatility, custody, liquidity, regulation, and accounting effects.

56 risks. Estelle remains an exploration-stage project with no commercial production, earnings, or identified mineral reserves.

12 risks, 3 new, 5 reworded since the prior year. The company added three risks tied to a proposed 900-acre South Carolina AI and hyperscale data center project that remains non-binding and unfinanced.

38 risks, 15 new, 13 dropped, 14 reworded since the prior year. Christensen Ranch and Burke Hollow ramp-ups through 2027 add technical, production, cost and permitting execution risk.

50 risks, 4 new, 1 dropped, 6 reworded since the prior year. Financing is more urgent: $12.3 million is budgeted through October 2027 against insufficient cash, including $8.2 million for research and development.

32 risks, 2 new, 9 reworded since the prior year. New $1.25 billion revolving credit facility creates explicit leverage, covenant, and debt-servicing risk through 2031.

27 risks, 1 new, 3 dropped, 6 reworded since the prior year. Lite Strategy now emphasizes its Litecoin Treasury Strategy and exposure to LTC price volatility alongside potential pre-clinical drug programs.

79 risks. Ocean Capital is a newly formed blank-check company with no operating history, revenue, or identified acquisition target.

59 risks, 36 new, 21 dropped, 12 reworded since the prior year. Risk focus shifts from aqueous ozone cleaning products to unproven AI data centers, including two campuses and a 10-year Cerebras lease.

44 risks. The company has substantial accumulated losses and depends on additional financing, with $219.7 million deficit and $13.0 million 2026 net loss.

31 risks, 5 new, 3 reworded since the prior year. SPAR investment, $2.6 million Note, and commercial relationship add concentrated financial, liquidity, execution, and conflict risks.

30 risks, 4 new, 8 dropped, 7 reworded since the prior year. Net loss widened to $16.6 million and accumulated deficit reached $82.2 million.

46 risks, 19 new, 22 dropped, 7 reworded since the prior year. Strategy shifted toward early-stage MC4R agonists for rare obesity disorders, including hypothalamic obesity and Prader-Willi syndrome.

22 risks, 3 new, 4 reworded since the prior year. Three years of losses and negative cash flow now create substantial doubt about NAII’s ability to continue as a going concern.

30 risks, 2 reworded since the prior year. Customer concentration sharply increased: two customers generated 68% of fiscal 2026 revenue, versus 42% in fiscal 2025.

35 risks, 5 new, 2 dropped, 7 reworded since the prior year. AI adoption, outsourcing and shared services create new operational, privacy and execution risks.

44 risks. GPU supply, third-party capacity, and data-center constraints dominate the operating risks.

14 risks, 10 new, 17 dropped, 4 reworded since the prior year. Risk disclosure now separately covers hotel competition, capital needs, regulation, cybersecurity and catastrophic events.

39 risks, 1 dropped, 5 reworded since the prior year. Backlog fell from $7.52 million to $6.96 million, with shipments now planned during fiscal 2027.

16 risks, 4 reworded since the prior year. The software risk now specifically covers vulnerabilities from third-party and open-source components, development tools, and dependencies.

52 risks, 1 new, 4 dropped, 10 reworded since the prior year. Geopolitical risk now emphasizes Russia sanctions, Middle East instability, Iran, oil and gas price volatility, and service demand.

34 risks. Risks span a China pharmaceutical distribution business and a newly launched AI compute and managed inference business with no revenue or customers yet.

40 risks, 4 new, 2 dropped, 6 reworded since the prior year. Nasdaq compliance risks intensified, with a $1 bid-price deadline, a new $5 million market-value rule, and possible delisting.

25 risks, 3 new, 3 dropped, 7 reworded since the prior year. Regulatory risks broaden to include undisclosed supervisory restrictions and accounting changes.

51 risks. Financing dominates, with $65–$75 million needed over twelve months and further debt, equity, and offtake funding required for Elk Creek.

36 risks, 3 new, 1 dropped, 13 reworded since the prior year. AI governance, fraud, and reputation threats receive new emphasis alongside community-bank cyber and compliance exposure.

22 risks, no changes since the prior year. No new, removed, or reworded risk factors were provided for this year.

20 risks, 2 new since the prior year. New risks focus on integrating the Facet acquisition and managing expanding artificial intelligence use.

31 risks, 2 new, 4 dropped, 9 reworded since the prior year. Strategic initiatives now emphasize system-wide execution, customer acceptance, branding backlash, training, and workforce stability across hundreds of stores.

64 risks, 7 new, 3 dropped, 11 reworded since the prior year. FDA layoffs and funding or staffing problems may delay Incannex’s drug reviews, approvals and inspections.

56 risks, 7 new, 9 reworded since the prior year. Lunar Initiatives now dominate risk disclosure, with unproven technology, funding dependence, acquisitions, competition, and execution uncertainty.

70 risks, 6 new, 4 dropped, 11 reworded since the prior year. New risks emphasize partner defaults, third-party infrastructure, AI use, Hungarian mining approvals, and higher reporting costs.

32 risks, 8 new, 4 dropped, 2 reworded since the prior year. FDA may reject a viable path for ersodetug in congenital HI or require a costly new randomized study after sunRIZE.

47 risks, 2 new, 1 dropped, 10 reworded since the prior year. Integrity received provisional Title IV eligibility through March 31, 2029, while its CCMCC acquisition required ownership-change recertification.

60 risks, 8 new, 3 dropped, 37 reworded since the prior year. New risks emphasize AI dependence, online subscription regulation, vendor compliance, import restrictions, and uncertain taxes.

24 risks, 3 new, 1 dropped, 10 reworded since the prior year. 2026 tariffs and retaliation increased ingredient, packaging, production, supply-chain and distribution costs, with possible demand declines.

66 risks, 5 new, 9 dropped, 25 reworded since the prior year. Capital access, proposed Ark and institutional digital asset acquisitions, and AtlasClearing’s regulatory and control obligations dominate this year’s changes.

36 risks, 4 new, 3 dropped, 6 reworded since the prior year. China manufacturing has been substantially wound down, with residual costs and obligations still uncertain.

112 risks. HYPE and the Hyperliquid Network are newly launched, with limited operating and performance history.

23 risks, 2 new, 1 dropped, 1 reworded since the prior year. Privacy compliance now specifically covers HIPAA and state requirements affecting NurseMagic™ and customers.

37 risks. Georgia utility-scale battery joint venture startup dominates near-term execution, funding, competition, supply, regulatory, and technology exposure.

59 risks, 2 dropped, 5 reworded since the prior year. Customer concentration increased to five customers representing 83% of fiscal 2026 gross revenue, versus four customers representing 85% previously.

33 risks, 10 new, 9 dropped, 18 reworded since the prior year. New risks specifically address connected, electric, hybrid and autonomous RV technology, including cybersecurity, privacy, regulation and charging infrastructure.

85 risks, 49 new, 14 dropped, 12 reworded since the prior year. AI model reliability, client-data protection, cross-client leakage, and AI-generated errors now dominate the risk section.

31 risks, 6 new, 1 dropped, 13 reworded since the prior year. A rights offering left the largest stockholder and affiliates with approximately 60% ownership and control over key shareholder votes.

117 risks, 26 new, 9 dropped, 23 reworded since the prior year. A $5.4 million goodwill impairment followed setbacks involving out-licensed assets and could recur if partners suspend development.

37 risks, 3 new, 4 reworded since the prior year. Fintech operations are now paused in both the US and UK, shifting the stated focus toward investment management.

50 risks, 7 new, 23 dropped, 24 reworded since the prior year. AI, privacy, cybersecurity and intellectual-property exposure now receives explicit emphasis as Nutanix expands AI capabilities and processes customer data.

46 risks, 8 new, 14 dropped, 4 reworded since the prior year. The company added significant risks regarding its new Solana treasury strategy, governance, and validator operations, while dropping industrial hemp and CBD regulatory risks.

31 risks, 1 reworded since the prior year. Paramount Gold Nevada Corp. updated its going concern risk with new financial figures for fiscal 2026.

91 risks, 22 new, 19 dropped, 34 reworded since the prior year. 5E Advanced Materials faces going concern doubts and needs substantial financing to develop its borates and lithium project.

123 risks. The risk section is dominated by the volatility, ecosystem concentration, and technological vulnerabilities of BNB and the BNB Smart Chain.

68 risks, 9 new, 13 dropped, 20 reworded since the prior year. Government funding now creates execution, dilution, milestone, governance, and commercialization risks through the proposed CHIPS Act award.

33 risks, 3 reworded since the prior year. Third-party control risk now focuses on developing proved undeveloped reserves and possible operator delays or cancellations.

51 risks, 7 new, 1 dropped, 2 reworded since the prior year. Seven new risks center on pre-revenue joint ventures, FDA approval of IKE technology, cash needs, and potential loss of invested capital.

41 risks, 4 new, 7 dropped, 16 reworded since the prior year. New risks add local concentration consequences, pension termination costs, accounting-estimate uncertainty, and future capital-rule effects.

66 risks. Data-center exposure is central: 59% of fiscal 2026 revenue came from data-center products, with demand linked partly to AI investment.

57 risks, 4 new, 1 dropped, 9 reworded since the prior year. AI adoption and a Supreme Court ruling create new operational, litigation, regulatory and cybersecurity exposures.

34 risks, 3 new, 1 dropped, 8 reworded since the prior year. International Business sale remains conditional on regulatory approvals and a nine-month credit-maturity extension, creating major transition uncertainty.

34 risks, 10 new, 2 dropped, 2 reworded since the prior year. Operating losses reached $73.4 million with an accumulated deficit of $333.5 million.